Trial
NCT04933227
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Stomach Neoplasms
Intervention
Atezolizumab
Why stopped
Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-14